Study on Carboplatin, Cabazitaxel, and Abiraterone for Treating Metastatic Castration Sensitive Prostate Cancer

Inclusion Criteria

• Able to provide written consent to participate in the study.
• Diagnosed with prostate cancer that has spread to other parts of the body.
• Have a high volume of metastatic disease, such as cancer in organs or multiple bone lesions.
• Have been on hormone therapy (ADT) for 3 months or less.
• Low testosterone levels (below 50 ng/dL) and continuing hormone therapy if not surgically castrated.
• In good general health with an ECOG performance status of 0 or 1.
• Have adequate blood cell counts and organ function based on specific lab tests.
• Men must use condoms during intercourse while on the study drugs and for 30 days after stopping treatment to prevent drug exposure to partners.
• Must be 18 years or older.

Exclusion Criteria

• Have previously received chemotherapy, PARP inhibitors, or immunotherapy for prostate cancer.
• Have taken abiraterone or enzalutamide for more than 2 weeks.
• Have had recent radiation therapy or major surgery.
• Have used other prostate cancer treatments recently, except for certain anti-androgens.
• Have a PSA level below 2.0 ng/mL at diagnosis.
• Have significant nerve damage (peripheral neuropathy) above a certain level.
• Have another active cancer that could interfere with the study.
• Have cancer that has spread to the brain unless stable and treated.
• Have severe psychiatric conditions or social issues that could affect participation.
• Have a history of not following medical advice or unable to consent.